Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial)
-
Published:2022-06
Issue:3
Volume:46
Page:100862
-
ISSN:0147-0272
-
Container-title:Current Problems in Cancer
-
language:en
-
Short-container-title:Current Problems in Cancer
Author:
Googe Paul B.,
Theocharis Stamatios,
Pergaris Alexandros,
Li Haocheng,
Yan Yibing,
McKenna Jr. Edward F.,
Moschos Stergios J.ORCID
Subject
Cancer Research,Oncology
Reference23 articles.
1. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol,2018
2. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol,2014
3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012
4. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma;Frederick;Clin. Cancer Res.,2013
5. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma;Wilmott;Clin. Cancer Res.,2012
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献